Starpharma Holdings Limited (SPL) is a biotechnology company with over 20 years of experience in developing dendrimer technology for pharmaceutical applications. Their mission is to help patients with significant illnesses, such as cancer, achieve improved health outcomes and quality of life through the application of their unique dendrimer technology.
Find out what a historical investment in Starpharma Holdings Limited would be worth today using our SPL stock calculator.
Buying SPL shares in Australia can be done through an online investing platform, such as Stake. Follow the simple steps below to start investing in Starpharma Holdings Limited in minutes.
Sign up with some I.D. and zero paperwork
Add funds to your account
Make your first investment in SPL
What is the ticker symbol of Starpharma Holdings Limited?
The ticker symbol for Starpharma Holdings Limited is SPL.
How much is one share of SPL?
One share of SPL is valued at $0.42 as of 20 November 2026.
What is the market capitalisation of Starpharma Holdings Limited SPL?
As of 20 November 2026 Starpharma Holdings Limited has a market cap of $200.41M.
What is the P/E ratio of SPL?
The Price to Earnings ratio of SPL is -23.31.
What is the Earnings Per Share of SPL?
The Earnings Per Share of SPL is -$0.02.
What is the 52-week high for Starpharma Holdings Limited stock?
The Starpharma Holdings Limited 52-week high stock price is $0.88.
What is the 52-week low for Starpharma Holdings Limited stock?
The Starpharma Holdings Limited 52-week low stock price is $0.31.
Can I buy SPL shares through Stake, an investing platform like CommSec, Selfwealth or Superhero?
Yes, the Stake investing platform allows you to buy SPL shares and over 13,000 more stocks and ETFs across the ASX and Wall St.
This is not financial product advice nor a recommendation to invest in the securities listed. Past performance is not a reliable indicator of future performance. As always, do your own research and consider seeking financial, legal and taxation advice before investing. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.